Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Diabetes, Obesity and Metabolism |
Vol/bind | 17 |
Udgave nummer | 2 |
Sider (fra-til) | 116-120 |
Antal sider | 5 |
ISSN | 1462-8902 |
DOI | |
Status | Udgivet - 1 feb. 2015 |
Bibliografisk note
Publisher Copyright:
© 2014 John Wiley & Sons Ltd.
ID: 305736654